Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211455418> ?p ?o ?g. }
- W3211455418 endingPage "1920" @default.
- W3211455418 startingPage "1910" @default.
- W3211455418 abstract "Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial ( NCT02899195 ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma." @default.
- W3211455418 created "2021-11-22" @default.
- W3211455418 creator A5001159835 @default.
- W3211455418 creator A5006560755 @default.
- W3211455418 creator A5012061864 @default.
- W3211455418 creator A5012798147 @default.
- W3211455418 creator A5018401879 @default.
- W3211455418 creator A5018666301 @default.
- W3211455418 creator A5021631207 @default.
- W3211455418 creator A5026185730 @default.
- W3211455418 creator A5034118773 @default.
- W3211455418 creator A5036721299 @default.
- W3211455418 creator A5045944556 @default.
- W3211455418 creator A5048216930 @default.
- W3211455418 creator A5051788681 @default.
- W3211455418 creator A5052688634 @default.
- W3211455418 creator A5056510071 @default.
- W3211455418 creator A5059543131 @default.
- W3211455418 creator A5061484013 @default.
- W3211455418 creator A5064012830 @default.
- W3211455418 creator A5066707073 @default.
- W3211455418 creator A5072460569 @default.
- W3211455418 creator A5079249587 @default.
- W3211455418 creator A5082613510 @default.
- W3211455418 creator A5088178599 @default.
- W3211455418 creator A5090069473 @default.
- W3211455418 creator A5090156519 @default.
- W3211455418 creator A5090856869 @default.
- W3211455418 creator A5091168604 @default.
- W3211455418 date "2021-11-01" @default.
- W3211455418 modified "2023-10-18" @default.
- W3211455418 title "Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial" @default.
- W3211455418 cites W1492563235 @default.
- W3211455418 cites W1517688143 @default.
- W3211455418 cites W1965766186 @default.
- W3211455418 cites W1999574084 @default.
- W3211455418 cites W2003892998 @default.
- W3211455418 cites W2007265317 @default.
- W3211455418 cites W2007541023 @default.
- W3211455418 cites W2022343354 @default.
- W3211455418 cites W2060004514 @default.
- W3211455418 cites W2070195376 @default.
- W3211455418 cites W2074640340 @default.
- W3211455418 cites W2076668534 @default.
- W3211455418 cites W2102627969 @default.
- W3211455418 cites W2112752664 @default.
- W3211455418 cites W2122221221 @default.
- W3211455418 cites W2136170412 @default.
- W3211455418 cites W2141663748 @default.
- W3211455418 cites W2150056019 @default.
- W3211455418 cites W2152061559 @default.
- W3211455418 cites W2179438025 @default.
- W3211455418 cites W2214699570 @default.
- W3211455418 cites W2215044613 @default.
- W3211455418 cites W2291531085 @default.
- W3211455418 cites W2329699996 @default.
- W3211455418 cites W2405513305 @default.
- W3211455418 cites W2562305489 @default.
- W3211455418 cites W2593193817 @default.
- W3211455418 cites W2734098379 @default.
- W3211455418 cites W2753188049 @default.
- W3211455418 cites W2766209631 @default.
- W3211455418 cites W2782124401 @default.
- W3211455418 cites W2783043796 @default.
- W3211455418 cites W2794804602 @default.
- W3211455418 cites W2796207838 @default.
- W3211455418 cites W2796582438 @default.
- W3211455418 cites W2801309958 @default.
- W3211455418 cites W2802476071 @default.
- W3211455418 cites W2802645166 @default.
- W3211455418 cites W2806103948 @default.
- W3211455418 cites W2806945293 @default.
- W3211455418 cites W2808133785 @default.
- W3211455418 cites W2808625215 @default.
- W3211455418 cites W2811060920 @default.
- W3211455418 cites W2867868648 @default.
- W3211455418 cites W2897299514 @default.
- W3211455418 cites W2897816153 @default.
- W3211455418 cites W2924359886 @default.
- W3211455418 cites W2938922501 @default.
- W3211455418 cites W2946234641 @default.
- W3211455418 cites W2948619068 @default.
- W3211455418 cites W2952203056 @default.
- W3211455418 cites W2966335450 @default.
- W3211455418 cites W2971466727 @default.
- W3211455418 cites W2978203211 @default.
- W3211455418 cites W2988620928 @default.
- W3211455418 cites W2995494055 @default.
- W3211455418 cites W2999445610 @default.
- W3211455418 cites W3013150773 @default.
- W3211455418 cites W3032355325 @default.
- W3211455418 cites W3036271806 @default.
- W3211455418 cites W3038765693 @default.
- W3211455418 cites W3042684909 @default.
- W3211455418 cites W3081696843 @default.
- W3211455418 cites W3088005314 @default.
- W3211455418 cites W3100266437 @default.
- W3211455418 cites W3106384965 @default.